Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Phase 2

An Open-label Study With Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT07933783 · tracked via the Priya Life Science USA tracker
Phase
Phase 2
Started
2026-10-26
Last updated
2026-11-12

Condition(s) studied

Plaque Psoriasis

Investigational drug(s) / intervention(s)

ORKA-002 →

ORKA-002: ORKA-002 administered by subcutaneous (SC) injection

Study summary

An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
79 Years
Healthy volunteers
No
Inclusion Criteria: 1. Signed informed consent by participants from previous trial choosing to transition into the Open-label study. 2. Participants who have successfully completed the preceding trial. 3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit. 4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception. Exclusion Criteria: 1. Participants who experienced any adverse events with ORKA-002 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-002. 2. Participants whom the Investigator feels would not benefit from treatment with open-label ORKA-002. 3. Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial. 4. Participants who, while in ORKA-002-212, developed a new intercurrent illness or diagnosis/suspected diagnosis which, in the opinion of the Investigator, indicates that continued treatment and/or participation in the study is not in the participant's best interest. 5. Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001. 6. Participant is pregnant or breastfeeding.

Primary outcome measure(s)

  • Incidence of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs of Special Interest (TEAESIs) — Day 1 through Week 144
    Incidence of treatment adverse events, serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms.

Trial sites (8)

FacilityCityRegionStatus
Oruka Therapeutics Investigative Site Fountain Valley California
Oruka Therapeutics Investigative Site Milford Massachusetts
Oruka Therapeutics Investigative Site New Brighton Minnesota
Oruka Therapeutics Investigative Site Wilmington North Carolina
Oruka Therapeutics Investigative Site Warrenton Oregon
Oruka Therapeutics Investigative Site Barrie Ontario
Oruka Therapeutics Investigative Site North Bay Ontario
Oruka Therapeutics Investigative Site Toronto Ontario
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07933783 on ClinicalTrials.gov ↗ ← All trials in the USA